

Fig. 52

52 / 129

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis
	Diversity	Equivalence	Total (+) Vs (-)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Total (+) vs (-)
DR	Diversity		Total	Total		Stomach	Stomach		Other cancers
5	arp_25	KR	K=R	K(-)>hetero Rhomo>hetero	RR78.8		RR71.4		
6	arp_24	FL	F=L		FI66.7	F(-)>(+)	LI60.9		
13	arp_17	AT	A=T	Ahomo>hetero, T(-) >hetero	AA76.6		AA67.8		
14	arp_16	AV	A=V	A(-)>hetero Vhomo>hetero	VV78.8		VV71.4		
29	arp_1	AS	A=S		SS83.36		SS100	A(+)>(-), St- >(+)	A Shomohetero> (-)
33	arp4	OR	O=R		OR68.3		RR68.1		
38	arp9	EKW	9K=11D=26Y=28H=30G		KW74.2		KW75.8		
39	arp10	EOY	10E=31V=38A=40Y= (166Q)=(166R)		EY83.3		EY75		
40	arp11	DGLPSV	11G=13Y=14E=14=K25 Q=25R=30L 11S=12K=12T, 11P=13R	V(-)>hetero	GV100, LL100Q		Vhetero>(-)	LL100	Phetero>homo
41	arp12	KT			KK66.5		TT70.7		
42	arp13	FGHRSY	13F=31F=31I		HY100, FR71.6		SY100, GR75.4	F(+)>(-)	Phetero>(-), Shetero(-) Shetero(-) >homo
43	arp14	EK	E=K		EE66.2		EK80		
45	arp16	HOY			HQ71.50	Qhetero> homo	HQ830		
55	arp25	OR	O=R						
55	arp26	FLY			LY70.2	Lhetero> homo	LY80.3		Phetero>homo
57	arp28	DEH	28H=30G		DE69.2		DE69.4		
59	arp30	CDHLRY	30H=37L=38L=85A=85V		CC1000		CC1000		
60	arp31	FIV	31V=38A=40F=40Y, 31 (F=I)		FV77.8		FV76.2	(+)>(-)	Phetero>homo (hetero>(-)

Fig. 53

53 / 129

				Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Total	Total (+) vs (-)	Total (homo)	Stomach	Stomach	Total (+) vs (-)	Total (homo)
DR	Diversity					Stomach	Stomach			Other cancers	Other cancers
61	arp32	HY	H=Y		HY66.9			YY68			
62	arp33	HN	H=N		NN66.7			HH71.4			
66	arp37	FLNSY	F=S		LL800			FS73.4			F(-) hetero>homo
67	arp38	ALV			LL800			AV78.8			
69	arp40	FY	F=Y		FY73.1			FY71.6			
76	arp47	FY	F=Y		FY67.4			YV68.9			
86	arp57	ADSV		Shetero (-)>homo	AV73.70			AD72.5			Shetero (-)> homo
87	arp58	AE	A=E		AE67			AE71.1			
89	arp60	HAY			HS73.7			HY68.4			
96	arp67	FIL			FI68.5			FI72.2			
99	arp70	DQR			DD69.4			DD72.7			
100	arp71	AEKR		K(-)>hetero	AR63.5, ER67.2, AE72.6		K(-)>(+)	K(-)>hetero			A.Ehetero> homo
	arp73	AG	73A=73G=74R=74N= 77N=77T		AA66.3			AA68.1			
103	arp74	AELOR	R=N		LR80			AQ100.0			
106	arp77	NT	N=T		TT66.4			TT68.2			
107	arp78	VV	V=Y		VY67.1			VY68.6			

54 / 129

Fig. 54

	Diversity	Equivalence	Prognosis Total (+) vs (-)	Prognosis Total (homo)	Prognosis Total	Prognosis Total (+) vs (-)	Prognosis Total (homo)	Prognosis Stomach	Prognosis Total (+) vs (-)	Prognosis Total (homo)
DR	Diversity		Total	Total		Stomach	Stomach		Other cancers	Other cancers
114	arp85	AV	A=V		AA80		VV68.1			
115	arp86	GV	G=V		GG68.5		VV69.4			
125	arp96	EHQY			EE100		EE100			Q(-) hetero>homo
127	arp98	EK	98E=98K=104A=142V		EK68.5		EK72.1			
133	arp104	AS	A=S		AS70.5		AS72.1			
149	arp120	NS	S=N		NN77.9		NN72.9			
				N(-) >hetero Stomo>h etero						
162	arp133	LR	133L=133R=142M=142V		RR67.5		LL69.7		R(+)>(-)	
169	arp140	AT			TT71.5		TT74.1			
171	arp142	MV	M=V		VV67.5		MM69.7		V(+)>(-)	
178	arp149	HQY	H=Q		HH68.1		HH70.8			
	arp164	FV								
195	arp166	QR	Q=R		RR67		QR68.6			
209	arp180	LV	L=V		LL75.1		RR68.6			
210	arp181	MT			TT67.3		LL70.1			
218	arp189	RS	R=S		SS100		TT69			
260	arp231	PQ	P=Q		QQ66.7		SS100			
262	arp233	RT	R=T		TT67.4		QQ67.9			
						T(+)>(+)	RR78.2			R Thetero(-) >homo
	All survived				DR11GLGV LL(5)		DR30CLC C(4)			

Fig. 55

		Prognosis	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect		
	Diversit	Equivalence	Other cancers	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)	Total (homo)	Stomach cancer
DR	Diversit		Total	Total			Stomach	Stomach	
arp_25	KR	K=R	RR100						
arp_24	FL	F=L	FL100						
arp_17	AT	A=T	AA100		Immunotherapy AA 71.4				
arp16	AV	A=V	VV100						
arp1	AS	A=S	AA90.90						
arp4	OR	O=R	OO69.3						
arp9	EKW	9K=11D=26Y=28 H=30G	KW71.2		Immunotherapy KW (86.7)		Immunotherapy E (-), (homo)>hetero	Immunotherapy KW 84.6	
arp10	EOY	10E=31V=38A=4 0Y=(166Q)=(166 R)	EY100	Immunotherapy E(-)>(+)	Immunotherapy E(-) >hetero		Immunotherap y E(-) >(+)	Immunotherapy E(-) >hetero	
arp11	DGLPS V	11G=13Y=14E=1 4=K25Q=25R=3 0L 11S=12K=12T, 11P=13R	LL1000	Immunotherapy V(homo,((-))>hetero	no adjuvant therapy DS(83.4)DV(79.6), Immunotherapy DP (84.6)		Immunotherapy V(homo,((-))>hetero		
arp12	KT		KK64.2						
arp13	FGHRS Y	13F=13F=31I	FR74.20	Immunotherapy Shetero> (- ,)homo	no adjuvant therapy GH(89.9), Immunotherapy FS(81.9)		Immunotherapy H(homo,((-))>hetero		
arp14	EK	E=K	EE63.5						
arp16	HOY		OY100						
arp25	OR	O=R							
arp26	FLY		LL100	Chemotherapy 26L(+)>(-)	Chemotherapy Lhetero>(-),homo, Immunotherapy Lhetero (-)>homo	no adjuvant therapy FL(87), Immunotherapy FL(61.4)	Chemotherapy Lhetero,((-))>homo, Immunotherapy Lhetero (-)>homo	Immunotherapy LY66.7	
arp28	DEH	28H=30G	EE83.3				Immunotherapy Ehetero,(-)>homo	Immunotherapy EH (68.6)	
arp30	CGHLR Y	30H=37L=38L=8 5A=85V	CC100	no adjuvant therapy H(+)>(-), Immunotherapy R(-)>(+)	Immunotherapy R(-) >hetero		Immunotherap y R(-)>(+)		
arp31	FIV	31V=38A=40F=4 0Y, 31(F=1)	FV80	Immunotherapy V(-)>(+)	Immunotherapy V (- >hetero	Immunotherapy FF (55.5), FI(60.7)	Immunotherap y V(-)>(+)	Immunotherapy V(-) >hetero	

Fig. 56

56 / 129

		Prognosis	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect	Treatment Effect
	Diversity	Equivalence	Other cancers	Total (+) vs (-)	Total (homo)	All cases	Total (+) vs (-)
DR	Diversity			Total			Stomach
arp32	HY	H=Y	HY64.6				Immunotherapy N(-)>P(+)
arp33	HN	H=N	HN64.5				Immunotherapy H(homo)>(-) hetero, Immunotherapy N(-)>P(homo), hetero
arp37	FLNSY	F=S	FL63.30	Chemotherapy F(-)>P(+) no adjuvant therapy L (+)>P(-), Immunotherapy N(+)>P(-)	Chemotherapy F(-) >hetero, homo, Immunotherapy N(hetero, homo)>P(-)	Chemotherapy LY(70.9), Immunotherapy NS(72.5)	
arp38	ALV		LL100	Immunotherapy AL(-)>P(+), no adjuvant therapy L(+)>P(-)	Immunotherapy AL(-) >hetero		Immunotherapy AL(-) >hetero
arp40	FY	F=Y	FY75	Immunotherapy Y(-)>P(+)	Immunotherapy F(homo)>hetero, Immunotherapy Y(-) >hetero	Immunotherapy FF(67.5)	
arp47	FY	F=Y	FY67.3				
arp57	ADSV		AV68.90	Chemotherapy A(-)>P(+)	no adjuvant therapy Shetero((-))>homo	no adjuvant therapy SV(92.2), Chemotherapy DD(60.3), Immunotherapy AD(76.2)	Chemotherapy FF(74.5) no adjuvant therapy SV(100) Immunotherapy AD(63.3)
arp58	AE	A=E	AA63.5	Chemotherapy H(-)>P(+)		Chemotherapy YY(56.8)	
arp60	HAY		HS68.9	Immunotherapy H(-)>P(+)			
arp67	FL		FF72.4	Chemotherapy L(-)>P(+)	Immunotherapy L(-) >homo, hetero, no adjuvant therapy L(hetero)>P(homo, Chemotherapy L(-) >hetero, homo	no adjuvant therapy IL(62.8), Chemotherapy FI(63.4), Immunotherapy FL(68)	Chemotherapy L(hetero)>P(-) Chemotherapy L(-) homo>hetero
arp70	QCR		RR69.4	Chemotherapy R(-)>P(+)			no adjuvant therapy D(hetero)>homo(-)
arp71	AEKR		KR78.80	no adjuvant therapy K(-) >P(+)	no adjuvant therapy A(hetero, (-))>homo, E(hetero, (-))>homo	no adjuvant therapy RR(81.8), Immunotherapy ER(73.7)	no adjuvant therapy K(-)>P(+)
arp73	AG	73A=73G=74 R=74N=77N=77I	AG66.6				Chemotherapy G(-)>P(+)
arp74	AELOK	R=N	ER1000	Chemotherapy E(-)>P(+) Immunotherapy E(+)>P(-)	Immunotherapy A(hetero, (-))>homo, Immunotherapy E(hetero, homo)>P(-)	Immunotherapy AE(67.9)	Chemotherapy R(-)>P(+)
arp77	NT	N=T	NT83.3				Chemotherapy N(-)>P(+)
arp78	VY	V=Y	VV69.3				Chemotherapy N(-) >hetero, Chemotherapy Thomo>hetero

58 / 129

Fig. 58

			Treatment Effect	Treatment Effect	DR	DR	DR	DR
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metastases	Total (ratio of advanced cancer)
DR	Diversity		Other cancers	Other cancers				
arp 25	KR	K=R						
arp 24	FL	F=L				FLB01122.90		
arp 17	AT	A=T						
arp 16	AV	A=V						
arp 1	AS	A=S			no adjuvant therapy AA (100)			AS733 AA44.40
arp4	OR	O=R						
arp9	EKW	8K=11D=26Y =28H=30G	no adjuvant therapy Whetelo (-) >homo		no adjuvant therapy KM (83.9)			
arp10	EQY	10E=31V=38A =40Y=(166Q) =(166R)						
arp11	DGLPSV	11G=13Y=14 E=14=K25Q= 25R=30L 11S=12K=12T .11P=13R	no adjuvant therapy Phetelo (-) >homo					
arp12	KT							
arp13	FGHRSY	13F=31F=31I	no adjuvant therapy Rhetelo (-) >homo Chemotherapy Shetelo (-)>homo Immunotherapy Shetelo (-) homo		no adjuvant therapy FR (90) Chemotherapy FR (72) Immunotherapy FS (100)		FT22.6, FF0, GR0 O	
arp14	EK	E=K						
arp16	HOY							QQ100, YY6, 30
arp25	OR	O=R						
arp26	FLY		Chemotherapy F (-) (hetero)>homo					
arp28	DEH	28H=30G	Chemotherapy (hetero)>homo		Chemotherapy EE (100)			
arp30	CDHLRY	30H=37L=38L =85A=86V						
arp31	FIV	31V=38A=40F =40Y, 31(F=I)						

59 / 129

Fig. 59

	Diversity	Equivalence	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	DR Cancer in Family	DR Metastases	DR Total (ratio of advanced cancer)	DR Smoking
DR	Diversity		Other cancers	Other cancers					
arp32	HY	H=Y	Chemotherapy Y(+)>(-) Immunotherapy Y(+)>(-) Chemotherapy H(-)>(+)	Chemotherapy H(-) (hetero) homo Immunotherapy hetero (-) (hetero) homo (-) Chemotherapy (hetero) homo (-) Immunotherapy (hetero) homo (-)	Chemotherapy HY(55.6) Immunotherapy HY(55.6)				
arp33	HN	H=N						HN(8.3), NN(9.80)	
arp37	FLNSY	F=S		Chemotherapy F(-) (hetero) homo, no adjuvant therapy Shetaro (-) (hetero) homo	no adjuvant therapy YY(81.3), Chemotherapy FS(100), Immunotherapy NS(60)	#			
arp38	ALV								
arp40	FY	F=Y							
arp47	FY	F=Y							
arp57	ADSV		Chemotherapy A(-)>(+)	Chemotherapy A(-)> (hetero) homo Immunotherapy Shetaro (-) (hetero) homo	no adjuvant therapy SV(81.8), Chemotherapy VV(85.7), Immunotherapy DS(78.8)				
arp58	AE	A=E							
arp60	HAY			Chemotherapy H(-) (hetero) homo	Chemotherapy SS(85.7) Immunotherapy H(75) no adjuvant therapy FF(85.7), LL(78.3)				
arp67	FIL								
arp70	DOR								
arp71	AEKR			no adjuvant therapy Ahetero((-))>homo	no adjuvant therapy AR(74.9)				
arp73	AG	73A=73G=74 R=74N=77N=77T							
arp74	AELOR	R=N	no adjuvant therapy L(-) (+)	no adjuvant therapy Ahetero (-)>homo	no adjuvant therapy (AE81), Chemotherapy (AE54.4)				
arp77	NI	N=I							
arp78	VY	V=Y							

Fig. 60

60 / 129

		Treatment Effect	Treatment Effect	Treatment Effect	DR	DR	DR	DR
	Diversity	Equivalence	Total (+) vs (-)	Total (homo)	Other cancers	Cancer in Family	Metastases	Total (ratio of advanced cancer)
DR	Diversity		Other cancers	Other cancers				
arp85	AV	A=V	Chemotherapy G(+)>(-)	Chemotherapy Ghomo hetero>(-)	Chemotherapy VV(96)	AV(8.7) AA(0)	#	
arp88	GV	G=V		no adjuvant therapy Q(-)	no adjuvant therapy HY(100)			#
arp98	EHQY			hetero>homo				
arp98	EK	98E=98K=104 A=104S	Immunotherapy K(+)>(-)	Immunotherapy Ehetero(-) phomo, Immunotherapy Khetero,homo>(-)	Immunotherapy EK(86.4)			
arp104	AS	A=S	Immunotherapy S(+)>(-)	Immunotherapy Ahetero(-) phomo, Immunotherapy Shetero,homo>(-)	Immunotherapy AS(81.9)			
arp120	NS	S=N	no adjuvant therapy	no adjuvant therapy	no adjuvant therapy RR(69.1)	#		#
arp133	LR	133L=133R=1 42M=142V	R(+)>(-)	Lhetero(-)>homo, no adjuvant therapy Rhomo hetero>(-)				
arp140	AT							
arp142	MV	M=V	no adjuvant therapy V(+)>(-)	no adjuvant therapy Mhetero(-)>homo, no adjuvant therapy Vhomo hetero>(-)	no adjuvant therapy VV(69.1)			
arp149	HQY	H=Q						
arp164	FV							
arp166	OR	O=R						
arp180	LV	L=V			no adjuvant therapy LV(100)	#		
arp181	MT							#
arp189	RS	R=S						
arp231	PO	P=O						
arp333	RT	R=T	Immunotherapy T(+)>(-)	Immunotherapy Rhetero(-) phomo, Immunotherapy hetero,homo>(-)	Immunotherapy RT(77.9)			
All	survived							

61 / 129

Fig. 61

			Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Prognosis	Treatment	Treatment	Treatment
		Equivalence	Total (+) vs. (-)	Total (homo)	Total (+) vs (-)	Total (homo)	Total (+) vs. (-)	Total (homo)	Other cancers	Other cancers	Effect Total (+) vs. (-)	Effect Total (homo)	All cases
DP	Diversity		Total	Total	Stomach	Stomach	Stomach	Stomach	Other cancers	Other cancers	Total	Total	
37	app8	LV 8L=8V=9F =11G=11L		LV67.4		VV77.8		LV64.70					
38	app9	FHY		FY68.2		YY85.7		FY65.80					
40	app11	GL G=L		GL67.3		LL77.8		GL64.70					
64	app35	FLY		FF68		FY76.90		LY68.8					
65	app36	AV A=V		AA65.7		AA80		AA100					
84	app55	ADE		AA65.7		AA80		AA100					no adjuvant therapy AD(79)
85	app56	AE		EE67.5		EE70.8		AA67.3					
86	app57	DE		DD68.5		DD76		EE64.2					
94	app65	FL	65I=65L	LL85.7		LL85.7		LL64.6					
98	app69	EK E=K		EK68.6		EK69.4		EK67.90					no adjuvant therapy E(81.4)
105	app76	IMV		II100		IV100		IM67.70					
113	app84	DG		DG68.9		GG70.8		DG65.9					
114	app85	EG		EG66.9		GG70.8		EG65.9					
115	app86	AP		AP66.9		PP70.8		AP65.9					

62 / 129

[illegible]

Fig. 63

	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Stomach cancer	Treatment Effect Total (+) vs (-)	Treatment Effect Total (homo)	Treatment Effect Other cancers	Treatment Effect Other cancers	DP Category (rate of malignancy)	DP Metastases
app8	Diversity	Stomach	Stomach			Other cancers	no adjuvant therapy Vheto(-)>phomo	no adjuvant therapy (LV)	VV95.2 LL89.60
app9	FHY	Immunotherapy y H(-)>(+)	Immunotherapy H(-) y (homo)>hetero	Immunotherapy FY(67.1) FF(65)	no adjuvant therapy F(+)>(-)	no adjuvant therapy Fhetero homo>(-), no adjuvant therapy H(-) hetero>homo	no adjuvant therapy (FY)	#	
app11	GL				no adjuvant therapy G(+)>(-)	no adjuvant therapy Chetero,homo>(-), no adjuvant therapy L(-) hetero>homo	no adjuvant therapy (GL)	VV95.2 LL89.60	
app35	FLY			Chemotherapy (FF)			Chemotherapy (LY)		#
app36	AV	Chemotherapy A(-) y (homo)>hetero Chemotherapy V(homo, (-) >hetero	Chemotherapy (VV)						
app55	ADE	Chemotherapy A(-) y (homo)>hetero			no adjuvant therapy A(+)>(-)	no adjuvant therapy Dhetero>(-)>homo	no adjuvant therapy DE(76.3)	AE44.8, AA10 0	
app56	AE				no adjuvant therapy A(+)>(-)	no adjuvant therapy Ahetero>(-)>homo, no adjuvant therapy Ehetero>(-) >homo	no adjuvant therapy AE(74.6)		
app57	DE				no adjuvant therapy E (+)>(-)	no adjuvant therapy Dhetero, (-)>phomo, no adjuvant therapy Ehetero,homo>(-)	no adjuvant therapy DE (76.8)	VV96.3 LL89.60	
app65	FIL				no adjuvant therapy L (+)>(-)	no adjuvant therapy lhetero>homo, no adjuvant therapy (lhetero,homo>(-), no adjuvant therapy E(-) hetero>homo, no adjuvant therapy lhetero,homo>(-)	no adjuvant therapy IL(100)		
app69	EK	Immunotherapy y E(-)>(+)	Immunotherapy E(-) y (hetero)>homo, no adjuvant therapy Khetero>homo>(-), Immunotherapy Khomo, hetero>(-)	no adjuvant therapy EK (55.4) Immunotherapy KK (58.3)	no adjuvant therapy K(+)>(-)		no adjuvant therapy EK(71.7)		
app76	INV		Chemotherapy (I(-), (homo)>hetero	Chemotherapy (MV(64)		no adjuvant therapy Vhetero, (-)>phomo	no adjuvant therapy MV(79)	VV95.6 LL86.70	
app84	DG							DD92.1 GG87.80	
app85	EG							EE92.1 GG87.60	
app86	AP							VV92.1 MM87.80	